Background. The natural history of chronic hepatitis B virus (HBV) infection was divided into 4 phases. Patients in the inactive carrier (IC) status and immune tolerant (IT) phase had normal alanine aminotransferase levels but huge different viral loads. The mechanism underlying low viral replication status in IC phase is unknown.
The natural history of chronic hepatitis B virus (HBV) infection can be divided into 4 phases including immune-tolerant (IT); immune-active (IA) or hepatitis B e antigen (HBeAg)-positive active chronic hepatitis; the inactive carrier status (IC); and HBeAg-negative active chronic hepatitis (ENH) [1] . In the IT phase, HBV serum load is extremely high (10 7 -10 9 IU/mL) with normal alanine aminotransferase (ALT) level. As the infection progresses, serum ALT levels of patients are usually elevated due to immune response-mediated hepatic cell destruction and liver injury. Although the host immune response usually does not clear HBV in the IA phase, HBV replication in the liver is strongly reduced [2] . In some chronic hepatitis B (CHB) patients in the IA phase, HBeAg may be seroconverted spontaneously without treatment [3] . CHB patients with HBeAg seroconversion become IC with normal ALT levels and low HBV loads, but are susceptible to HBV reactivation with ALT flares [4] . Importantly, the host immune system plays a critical role in the development of chronic HBV infection with aforementioned different manifestations [5] .
Numerous evidences have indicated that CD8 + T cells contribute to viral clearance during primary acute HBV infection and in mediating viral control during chronic HBV infection [6] . Vigorous, multispecific CD8 + T-cell responses to HBV proteins have been shown in acutely infected patients who cleared HBV infection [7, 8] whereas CHB patients have no or low T-cell responses directed against HBV [9] . Higher levels of HBV-specific CD8 + T cells are beneficial for the control of HBV replication, thereby are protective against liver injury mediated by unspecific immune responses [10] . The innate immune responses have also been shown to suppress the HBV infection [11, 12] . A number of interferon-stimulated genes (ISGs) are able to reduce HBV replication and gene expression [10, [13] [14] [15] [16] [17] [18] . Activation of Toll-like receptor (TLR)-mediated signaling in hepatocytes and other cell types exerts direct antiviral effects in hepatocytes or triggers the production of interferons (IFNs) and proinflammatory cytokines with antiviral activities [13, [19] [20] [21] . However, a recent study found that patients had similar global T-cell cytokine and HBV-specific T-cell profile in blood between the IT and IC phases [22] . And gene expression analysis of liver biopsy tissue shows intrahepatic covalently closed circular DNA and HBV replication levels does not correlate with lymphotoxin pathway gene expression [23] . Lately, 2 studies have been conducted to comprehensively analyze the expression of partial intrahepatic genes and showed that innate IFN and B-cell responses were highly active during the IT and IA phases [24, 25] , but liver biopsy transcriptomes were not compared between the IT and IC phases. As we know, both the IT and IC phase are characterized with low or mild liver necroinflammation or fibrosis, but they have hugely different viral load. Currently, the mechanism underlying low viral replication status in IC phase remains largely unknown.
Here, we selected 83 patients in 4 phases of chronic HBV infection and comprehensively analyzed intrahepatic gene expression profiles between the IT and IC phases. Moreover, we examined the effect of differently expressed genes on HBV replication in HBV-replicative cellular models.
MATERIALS AND METHODS

Tissue Samples From Study Subjects
Eighty-three CHB patients were recruited at the Huashan Hospital, Ruijin Hospital, Renji Hospital, and Public Health Center in Shanghai, China. All patients were diagnosed with chronic HBV infection. The natural history of chronic HBV infection was divided into 4 phases according to the European Association for the Study of the Liver guidelines [1] : (1) IT phase: normal ALT <40 IU/mL, HBeAg positive, high levels of HBV replication; (2) IA or HBeAg (+) active chronic hepatitis: elevated ALT >40 IU/mL, HBeAg positive, and relatively lower level of replication compared to the IT phase; (3) IC phase: normal ALT <40 IU/mL, antibody to HBeAg (anti-HBe) positive, low serum HBV DNA loads <2 × 10 3 IU/mL; (4) HBeAg (-) active chronic hepatitis: elevated ALT >40 IU/mL, anti-HBe positive, and serum HBV DNA loads >2 × 10 3 IU/mL. IA and ENH patients were classified as having active chronic hepatitis (ACH), and the liver histological data corresponded with the serological and virological parameters [26] .
The patients enrolled in the study had not received antiviral therapy or immunosuppressive drugs within the 6-month period prior to sample collection. Individuals with concurrent hepatitis C virus infection, hepatitis D virus infection, human immunodeficiency virus infection, autoimmune liver disease, primary biliary cirrhosis, alcoholic liver disease, Wilson disease, or any other coexisting primary liver disease were excluded. The study was approved by the local ethics committee and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. Written informed consent was obtained from each patient.
Liver biopsy was performed in all patients and the samples were obtained percutaneously with a Menghini needle. A part of the biopsy was used for routine histopathological diagnosis and then sent to Shanghai Biotechnology Co, Ltd, for microarray analysis. In addition to the biopsy samples, serum samples were also collected from all patients and were used for quantification of HBV DNA loads and other relevant clinical parameters. Patient characteristics, including the clinical features, are shown in Table 1 .
Affymetrix RNA Chip Microarray Analysis
Liver biopsies from the patients were subjected to RNA extraction and microarray analysis using the Affymetrix Human Genome U133 Plus 2.0 Array. The fluorescence intensity values were normalized using robust multichip averaging with GeneSpring 10 software. The differentially expressed genes were identified by one-way analysis of variance and t test unpaired unequal variance. The enrichment analysis of GO (Gene Ontology) terms, and KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses were performed using R version 3.0.1. (http: //www.r-project.org) and the package BioConductor 2.11 (http://www.bioconductor.org). Custom Perl scripts were written to extract and compare the differential gene expression of T-cell pathway, Toll-like pathway, and ISGs according to the KEGG pathways [27] and Schoggines et al [28] , respectively.
Cell Culture and Transfection
Human hepatoma cell lines HepG2 and Huh7 were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin, and maintained at 37°C in a humidified 5% CO 2 atmosphere. HepG2.2.15 cells with integrated dimers of the HBV genome (GenBank accession number U95551) were cultured with 500 μg/mL of G418 (Sigma-Aldrich, Steinheim, Germany). Primary human hepatocytes were isolated from liver transplantation donor by perfusion and cultured as described before [18] . Plasmids and small interfering RNAs (siRNAs) were transfected into cells at indicated concentrations by using Lipofectamine 2000 (Invitrogen, Carlsbad, California) according to the manufacturer's instructions.
siRNAs and Plasmids
All siRNAs used in the present study are listed in Supplementary  Tables 1 and 2 . The siRNA-nonspecific negative control was purchased from Dharmacon (siRNA-C, siGENOME NonTargeting siRNA No. 2; catalog number D-001210-02. Lafayette, Colorado). A HBV replication-competent clone pSM2 harboring a head-to-tail tandem dimer of the HBV genome (GenBank accession number V01460, genotype D) was provided by Dr Hans Will (Heinrich-Pette-Institute, Hamburg, Germany). EVA1A coding region (nt 479-937) was amplified from liver complementary DNA (cDNA) samples using primers listed in the Supplementary Table 3 . The polymerase chain reaction (PCR) products were ligated with pcDNA3.1/V5-His TOPO TA vector (Invitrogen), resulting in the expression plasmid pEVA1A.
Analysis of HBV Replication and Gene Expression
HBV replicative intermediates from intracellular core particles were extracted from hepatoma cell lines and detected by Southern blot, according to the protocols published previously [20] . Densitometry of nucleic acid bands for Southern blot was performed by using Image-Pro Plus software (Media Cybernetics, Silver Spring, Maryland). The values of the densitometric analysis were presented below each of the blots as the percentage of control samples. The levels of hepatitis B surface antigen (HBsAg) and HBeAg in culture supernatants were determined by using the Architect system and HBsAg and HBeAg chemiluminescent microparticle immunoassay kits (Abbott Laboratories, Wiesbaden-Delkenheim, Germany) according to the manufacturer's instructions.
Western blot analysis, RNA extraction, and real-time reverse-transcription (RT) PCR assay, serum cytokines, and HBV-specific T-cell responses detection in CHB patients are described in the Supplementary Materials and Methods.
Statistical Analysis
The statistical analysis was carried out using GraphPad (GraphPad Software, San Diego, California). Analysis of variance with Student t test was used to determine significant differences in multiple comparisons. P < .05 was considered as statistically significant. Data were presented as standard error of the mean.
RESULTS
Selection of CHB Patients for the Study
In this study, 220 of 1521 enrolled CHB patients underwent biopsies for routine diagnosis. Histological examinations of liver biopsies were performed to exclude fatty liver diseases and other liver diseases. The infection phase (IT, IA, IC, or ENH) of the enrolled patients was determined exclusively on the basis of serological and biochemical parameters as mentioned above. Twenty-two, 36, 11, and 14 patients in the IT, IA, IC, and ENH phases were selected, respectively. The liver histological data were corresponded with the serological and virological parameters. Consistently, the patients in the IT and IC phases had low G-and S-scores of 0-1 according to the Scheuer criteria, whereas >50% of IA patients had high G-and S-scores of 2-4. The flowchart for the selection of patients for the present study is shown in Supplementary Figure 1 . Detailed clinical information of patients is presented in Table 1 . The 83 collected liver biopsies were used for performing microarray analysis.
Activation Innate and Adaptive Immune Responses in Patients With
Active Chronic Hepatitis
To understand the role of host innate and adaptive immune responses in the natural history of chronic HBV infection, we systemically compared 8 immune-relevant pathways according to the KEGG database and a set of 387 ISGs in IT, IC, and ACH patients ( Table 2 ). The expression of genes related to T-cell receptor signaling, natural killer (NK) cell-mediated cytotoxicity, and ISGs was significantly higher in ACH patients than IT and IC patients, indicating activation of innate and adaptive immune responses in ACH patients. In contrast, the expression of genes related to B-cell receptor signaling pathway, antigen processing and presentation, and TLR signaling pathway showed no statistically significant difference among the 3 groups. Thus, T-cell and NK-cell responses as well as ISGs may play a role in the suppression of HBV replication and immunopathology in ACH patients.
In addition, a set of representative TCR markers, including CD3G, CD4, CD8A, CD8B, IL2RG, CD80, CD86, TNF-α, and CTLA4, were further analyzed and they showed an increased expression in ACH patients ( Figure 1A) . However, PDCD1 expression was similar in all 3 groups ( Figure 1A) . Similarly, the expression of the genes involved in NK cell-mediated cytotoxicity was significantly upregulated in ACH patients but was not significantly changed in the other 2 groups ( Figure 1B ). Some ISGs, including Mx1, IFIT1, CXCL10, STAT1, and APOBEC3B, showed a significantly elevated expression in ACH patients compared with IT and IC patients ( Figure 1C ). However, the selected genes' expression related to ISGs, T-cell, and NK-cell function decreased in IC patients and tended to be lower than that of IT patients.
Serum Cytokine Levels and HBV-Specific T-Cell Responses Were Similar
Between IT and IC Patients HBV-specific T cells has been considered to contribute to suppresses HBV replication. In our study, 45 patients were screened and 14 patients with chronic HBV infection in the Huashan Hospital from June 2015 to November 2015 were enrolled for HBV-specific T-cell response detection. Patients were divided into IT (n = 5) and IC (n = 9) groups based on their HBV infection state. We observed that HBV-specific T-cell responses were similar between IT and IC patients (Supplementary Figure 2) . Furthermore, we detected the serum cytokine levels including interleukin (IL) 6, IL-8, IL-10, IL-1b, IL-12p70, and tumor necrosis factor alpha (TNF-α) among IT, ACH, and IC patients and consistently no significant difference was observed between IT and IC groups (Supplementary Figure 3) . The intrahepatic immune-related gene expression profiles of IT and IC patients were largely similar but significantly different on TLR signaling pathway ( Table 2) . A statistical analysis revealed that 109 genes were significantly differentially expressed (with P < .01) in these 2 patient groups. Fifty-four genes in IC patients were significantly higher than those in IT patients, while other 55 genes in IC patients were significantly lower than those in IT patients ( Figure 2 ; Table 3 ). Among the 109 genes analyzed, only a few genes such as HLA-E, LAMP3, CCL19, and HLA-C, were known to be immune response genes. Other analyzed genes might involve in various biological processes such as cell metabolism and growth. Genes with unknown functions and no established associations with HBV infection progression were also identified (Supplementary Table 4 ). Furthermore, we hypothesized that at least a part of differentially expressed genes identified in IT and IC patients might participate in regulation of HBV replication in hepatocytes. To verify this hypothesis, siRNAs specifically targeting the 109 selected genes were applied to HepG2. Detailed information for identification of significant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with differently expressed genes by comparison of IT, ACH, and IC groups is presented in Supplementary Table 7 . Genes involved in the TLR signaling pathway, T-cell receptor signaling pathway, B-cell receptor signaling pathway, and interferon-stimulated genes were compared separately among 3 groups and are presented in Supplementary C5orf56  CAMK1  FHAD1  PYCOX1L  CCDC88A  LAMP3  MEF2C  AACSP1  ADIRF  KCNN3  MARVELD3  ARRDC3  MYRF  ZCWPW2  ADCY5  SETMAR  FJX1  LOC286114  RUNX1-IT1  ZBTB7A  ZNF207  RAVER2  CCL21  CCL19  CCND2  ARHGEF6  GBP2  TSC22D3  FCRL3  IL2RB  MS4A1  HLA-C  TTF2HLA-E  TLDC1  TNFAIP3  UTRN  NLRP1  VAMP1  ZNF117  CLHC1  TANC2  ABCA11P  LOC100129637  MTHFD2L  LOC100128288  MYO16  INPP1  KPNA5  APBB1  IGHMBP2  ASIP  OFCC1  TOMM34  GRAP  RANBP17  SERINC2  FREM2  HIGD1AP1  HOXD3  SMIM11  PLK3  CSTF2  PPIC  SRA1  PSMC4  EVA1A  SLC39A11  LRRC27  NDUFA2  KCNC3  MANEAL  SCFD2  SEL1L  BDH2  TIMM13  CRTC1  SLC25A21  MARK2  CCDC138  EFCAB1  MPP5  HNRPLL  LOC440982  ZIC1  LILRB4  IRF9  TMSB15B  ZMYM3  SETD6  CELSR3  CAMSAP1  GLRA3  CTNNA2  RNASET2  GP2  SAMD11  SPATA12  MYEOV  RREB1  WRAP73  EEF1DP3  TMED4  ZNF35 Gene name -2 2 Figure 2 . Differentially expressed genes in the immune tolerant (IT) and inactive carrier state (IC) patients. The intrahepatic gene expression profiles of IT and IC patients were determined by using Affymetrix Genechip Human Genome 133. The results were analyzed with Genespring 10 software. One hundred nine differentially expressed genes with P < .01 were identified for these 2 patient groups. Compared with IT patients, the IC patients showed elevated expression in 54 genes and down-regulated expression in 55 genes in the liver. The up-and down-regulation of these genes are presented in the heat maps.
Next, these genes that showed significant effect on HBV replication were selected for verification in Huh7 cells by transient transfection. Huh7 cells were cotransfected with siRNAs and the pSM2 plasmid with a replication-competent HBV dimeric genome (Supplementary Figure 5) . Last, we selected 5 genes (MANEAL, TOMM34, ZMYM3, EVA1A, and CSTF2) that consistently led to increased HBV replication and gene expression in both Huh7 and HepG2. Table 6) . At least 2 different siRNA sequences were used to target each of the 5 genes and the enhancing effect of gene silencing on HBV replication was verified (data not shown).
Expression of the Selected Genes During the Different Phases of HBV
Infection
According to the gene array results, EVA1A, TOMM34, MANEAL, ZMYM3, and CSTF2 were expressed higher in IC than IT patients, whereas EVA1A and ZMYM3 are expressed at similar levels between IT and ACH patients ( Figure 3C ). Moreover, serum HBV DNA levels and the intrahepatic expression levels of these genes were analyzed using linear regression. The hepatic expression of EVA1A, TOMM34, and MANEAL showed a negative correlation with serum HBV DNA loads, but not ZMYM3 and CSTF2 ( Figure 3D ). We also detected the expression of the selected genes in HepG2.2.15, Huh7 cells and primary hepatocytes by stimulation with IFN-α and IFN-γ using real-time PCR. We found that the expression levels of these genes were not changed after stimulation with recombinant human IFN-α and IFN-γ at concentrations of up to 1000 U/mL (Supplementary Figure 6) . The data indicated that the regulation of the selected genes was not comparable to that of other immune-related genes, and lower HBV replication during the IC phase was correlated with enhanced expression of the selected genes.
Verification of the Involvement of EVA1A in the Control of HBV Replication
Knocking down of EVA1A had a strong effect on enhancing HBV replication ( Figure 3A) . Consistently, transfection of siEVA1A enhanced HBV replication in HepG2.2.15, even at a low dose of 10 nM. HBsAg but not HBeAg expression was increased significantly by transfection with a high concentration of siEVA1A ( Figure 4A ). In contrast, EVA1A overexpression resulted in considerable suppression of HBV replication and gene expression in transiently transfected Huh7 cells in a dose-dependent manner ( Figure 4B ). The knockdown efficiency of siRNA targeting EVA1A was verified by Western blot and real-time RT-PCR ( Figure 4C) , and the overexpression of EVA1A was examined by Western blot detection of the V5 epitope ( Figure 4D ). Moreover, EVA1A knockdown had no significant effect on HepG2.2.15 cell viability compared to respective control (Supplementary Figure 7) . These findings demonstrate that EVA1A is involved in regulation of HBV replication without cytotoxicity.
DISCUSSION
The natural history of chronic HBV infection was divided into 4 phases according to the different immune status. Previous studies have shown that the magnitude of HBV-specific T-cell responses in chronically infected patients was inversely correlated with the viral loads and the extent of liver injury [29, 30] . Consequently, it has been previously proposed that a robust specific T-cell response suppresses HBV replication and reduces the infiltration of unspecific immune cells, and thereby prevents continuous liver damage [29] . In our study, liver biopsies were collected from 83 HBV-infected patients in IT, IA, IC, and ENH phases and the intrahepatic gene expression profiles were characterized and compared. The gene expression profile data indicated that both innate and adaptive immune responses were activated in ACH patients compared to IT and IC patients, including TCR signaling, NK cell-mediated cytotoxicity, and ISGs, which agrees with recent reports [22, 24, 31] . This finding is also consistent with the decrease of viral loads in ACH patients and with clinical manifestations such as increased ALT levels associated with immune-mediated liver injury [10, 20] .
The IT phase has been long considered lacking of disease progression and T-cell immunity, and low viral replication in IC phase was deemed to immune control [33] . However, a series of recent articles reported that HBV-specific T-cell responses may be also present in the IT phase of CHB, indicating that the so-called IT phase with extremely high viral load is not indeed devoid of immune activity [30, 34] . A recent study found that T-cell cytokine and HBV-specific T-cell profile in blood were similar between IT and IC phases [22] . In our study, the intrahepatic immune-related gene expression profiles between IT and IC patients were largely similar, such as TCR signaling, NK cellmediated cytotoxicity, ISGs, B-cell receptor signaling pathway, and antigen processing and presentation pathway. Furthermore, we analyzed the HBV-specific T-cell responses in vitro between IT and IC patients and found no difference between the 2 groups. This finding supports the intrahepatic TCR signaling gene expression profile between IT and IC patients and is consistent with previous report [22] . We also observed that several cytokines, such as IL-1β, IL-6, IL-8, IL-10, IL-12p70, and TNF-α, were comparable between IT and IC phases, as reported by Vanwolleghem et al [24] . Thus, we speculate that the control of HBV replication in IC phase was achieved by host factors distinct from the immune system. The absence of inflammation and low ALT values also indicate that immune-related liver damage is low during the IC phase.
In the study, a total of 109 genes were found to be differentially expressed in IC and IT patients. Interestingly, the identified genes were not immune response genes and were not inducible by IFN-α and IFN-γ in HepG2.2.15, Huh7 cells, and primary hepatocytes. Our attempt to functionally characterize the differentially expressed genes by performing gene silencing in 2 hepatoma cell lines, HepG2.2.15 and Huh7, led to the identification of a number of selected candidate genes with anti-HBV activities. In HepG2.2.15 cells, HBV replication was enhanced or decreased after silencing of 49 of the selected candidate genes. The data obtained by using transiently transfected Huh7 cells indicated that at least 5 differently expressed genes are involved in the control of HBV replication. The expression of the selected genes was not altered in IFN-α-and IFN-γ-treated hepatoma cells and primary hepatocytes. Several candidate genes such as EVA1A and ZMYM3 had comparable expression levels in IT and IA phase; however, the expression of candidate genes was elevated in IC patients. Although the role of the candidate genes in controlling HBV replication has not yet been elucidated, the genes are involved in several pathways that may be potentially influential in controlling HBV replication. For example, EVA1A has been reported to participate in the autophagy process [35, 36] . Recently, 2 groups demonstrated that HBV may exploit the autophagy process to enhance its replication [37, 38] . Thus, the candidate genes may have diverse functions, indicating that the control of HBV replication during the IC phase may be based on a broad network of various cellular processes. Future studies are needed to elucidate the functions of these selected genes and to identify novel therapeutic targets for treating chronic HBV infection.
There are some limitations to our study. The approach chosen in this study could only identify the genes that directly influence HBV replication in hepatocytes. In addition, the expression of these genes in hepatoma cell lines may not be representative of the expression pattern in vivo. In addition, we cannot exclude the possibility of altered expression of some of the candidate genes as a result of bystander effect and that the identified genes may not be related to HBV replication at all. More functional gene studies are needed to elucidate the role of the candidate genes in the control of HBV replication and the establishment of the inactive carrier status.
Taken together, we identified immune-related pathways were activated in ACH patients and a number of host genes that are distinct from the immune response genes and that are involved in the control of HBV replication in patients with inactive carrier status.
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